Cargando…

Novo, S. et al. Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors? Pharmaceuticals 2009, 2, 118-124

Detalles Bibliográficos
Autores principales:	Novo, Salvatore, Fazio, Giovanni, Raccuglia, Elena, Mignano, Antonino, Novo, Giuseppina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2011
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060125/ https://www.ncbi.nlm.nih.gov/pubmed/27721326 http://dx.doi.org/10.3390/ph4101293

Ejemplares similares

Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors?
por: Novo, Salvatore, et al.
Publicado: (2009)

Structural Predestination of Individual Diversity in the Course and Severity of Infectious Diseases
por: Rumyantsev, Sergey N.
Publicado: (2002)

Reverse remodeling and arrhythmic burden reduction in a patient with an implantable cardioverter defibrillator treated with sacubitril/valsartan: Case report
por: Corrado, Egle, et al.
Publicado: (2020)

Management of Direct Oral Anticoagulants in Patients with Atrial Fibrillation Undergoing Cardioversion
por: Coppola, Giuseppe, et al.
Publicado: (2019)

ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs
por: Lee, Ivan T., et al.
Publicado: (2020)

Controversy regarding ACE inhibitors / ARBs in COVID-19
por: Soria Arcos, Federico, et al.
Publicado: (2020)

ASSOCIATION BETWEEN IN-HOSPITAL MORTALITY AND ACE/ARB INHIBITOR USAGE
por: Ruge, Max, et al.
Publicado: (2022)

COVID-19-related deaths not increased with ACE inhibitor or ARB use
Publicado: (2020)

The effect of ACE inhibitors and ARBs on outcomes in hospitalized patients with COVID-19
por: Najafi, Narges, et al.
Publicado: (2022)

What Evidence Supports Guidelines for Use of ACE Inhibitors and ARBs in Diabetes?
por: Curtiss, Frederic R.
Publicado: (2006)

La déclaration de foi sur la prédestination par l'Eglise réformée du Japon /
por: Morikawa, Hajime
Publicado: (1996)

Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy
por: Sureshkumar, Kalathil K
Publicado: (2008)

Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients
por: Rossi, Gian Paolo, et al.
Publicado: (2020)

The concern about ACE/ARB and COVID-19: Time to hold your horses!
por: Pergolizzi, Joseph V., et al.
Publicado: (2020)

ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients
por: Daoud, Ahmed, et al.
Publicado: (2021)

ACE-I/ARB Therapy prior to Contrast Exposure: What Should the Clinician Do?
por: Kalyesubula, Robert, et al.
Publicado: (2014)

The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19
por: Braude, Philip, et al.
Publicado: (2020)

SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs
por: Ciulla, Michele M.
Publicado: (2020)

Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs
por: Byttebier, Geert, et al.
Publicado: (2021)

Just a few days left
Publicado: (2005)

Aliskiren, ALTITUDE, and the implications for ATMOSPHERE
por: McMurray, John J.V., et al.
Publicado: (2012)

COVID-19: The Influence of ACE Genotype and ACE-I and ARBs on the Course of SARS-CoV-2 Infection in Elderly Patients
por: Sieńko, Jerzy, et al.
Publicado: (2020)

Antihypertensive medication uses and serum ACE2 levels: ACEIs/ARBs treatment does not raise serum levels of ACE2
por: Emilsson, Valur, et al.
Publicado: (2020)

Continue ACE inhibitors / ARB’S till further evidence in coronavirus disease 2019 (COVID-19)
por: Bansal, Sandeep, et al.
Publicado: (2020)

Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis
por: Flacco, Maria Elena, et al.
Publicado: (2020)

NO EXCESS MORTALITY ASSOCIATED WITH CONCOMITANT ACE INHIBITOR OR ARB USE IN HOSPITALIZED PATIENTS WITH COVID-19
por: Annie, Frank H., et al.
Publicado: (2021)

ACE Inhibitor and ARB Utilization and Expenditures in the Medicaid Fee-For-Service Program from 1991 to 2008
por: Bian, Boyang, et al.
Publicado: (2010)

Aliskiren: An orally active renin inhibitor
por: Wal, Pranay, et al.
Publicado: (2011)

Aliskiren and the dual complement inhibition concept
por: Perez-Gomez, Maria Vanessa, et al.
Publicado: (2019)

Direct Renin Inhibition: Focus on Aliskiren
por: Pool, James L.
Publicado: (2007)

SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy
por: Chung, Mina K., et al.
Publicado: (2020)

Safety of ACE-I and ARB medications in COVID-19: A retrospective cohort study of inpatients and outpatients in California
por: Rubin, Samuel J. S., et al.
Publicado: (2021)

In silico prediction of ARB resistance: A first step in creating personalized ARB therapy
por: Anderson, Shane D., et al.
Publicado: (2020)

Role of aliskiren in blood pressure control and renoprotection
por: Trimarchi, Hernán
Publicado: (2011)

Aliskiren and valsartan combination therapy for the management of hypertension
por: Epstein, Benjamin J
Publicado: (2010)

Peripheral artery disease: potential role of ACE-inhibitor therapy
por: Coppola, Giuseppe, et al.
Publicado: (2008)

Cardiovascular risk reduction by reversing endothelial dysfunction:ARBs, ACE inhibitors, or both? Expectations from The ONTARGET Trial Programme
por: Ruilope, Luis Miguel, et al.
Publicado: (2007)

149 Association of ACE-I and ARB Prescriptions With Mortality in Patients Admitted to the Hospital With COVID-19 in New York City
por: Barrett, B., et al.
Publicado: (2020)

Cardiopulmonary Exercise Testing in Patients with Chronic Heart Failure: Prognostic Comparison from Peak VO2 and VE/VCO2 Slope
por: Sarullo, Filippo Maria, et al.
Publicado: (2010)

Aliskiren in hypertension: evidence for its potential therapeutic value
por: Peter, Doris
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_ghdb0uputsarkqm37v5gedjdm4